Comparative Pharmacology
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus ESTRASORB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus ESTRASORB.
DIETHYLSTILBESTROL vs ESTRASORB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic nonsteroidal estrogen that binds to estrogen receptors (ERα/ERβ), activating estrogen-responsive gene transcription, leading to proliferation of estrogen-sensitive tissues.
Estradiol, the primary estrogen component, binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene transcription and protein synthesis to replace deficient endogenous estrogen, alleviating menopausal symptoms.
0.5-2 mg orally once daily for palliative treatment of advanced prostate cancer; 5-15 mg orally once daily for prevention of postpartum breast engorgement.
One or two 0.87 mg estradiol transdermal packets (0.87 mg to 1.7 mg estradiol per day) applied once daily to the upper thigh or upper arm. Rotate application sites.
None Documented
None Documented
Clinical Note
moderateDiethylstilbestrol + Digoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDiethylstilbestrol + Digitoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDiethylstilbestrol + Deslanoside
"Diethylstilbestrol may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDiethylstilbestrol + Acetyldigitoxin
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) in adults; prolonged in hepatic impairment.
The terminal elimination half-life for estradiol is approximately 12-14 hours. This supports once-daily or twice-weekly dosing intervals for transdermal systems like ESTRASORB.
Primarily renal (90% as glucuronide and sulfate conjugates), with less than 5% excreted unchanged in urine; biliary/fecal elimination accounts for about 10%.
Estradiol and its metabolites are primarily excreted in urine (about 90%) and feces (about 10%). Biliary excretion contributes to fecal elimination. Renal clearance accounts for the majority of systemic clearance.
Category C
Category C
Estrogen
Estrogen
"Diethylstilbestrol may decrease the cardiotoxic activities of Acetyldigitoxin."